Prime Capital Investment Advisors LLC Sells 23,316 Shares of Johnson & Johnson $JNJ

Prime Capital Investment Advisors LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 21.8% during the 2nd quarter, Holdings Channel reports. The fund owned 83,719 shares of the company’s stock after selling 23,316 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Johnson & Johnson were worth $12,788,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in JNJ. Highline Wealth Partners LLC raised its position in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC bought a new position in Johnson & Johnson in the first quarter worth approximately $47,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson in the first quarter worth $48,000. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson in the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson in the first quarter worth $52,000. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $189.75 on Thursday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $190.22. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a fifty day moving average price of $177.49 and a 200 day moving average price of $163.37. The firm has a market cap of $456.98 billion, a price-to-earnings ratio of 20.29, a P/E/G ratio of 2.41 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the business earned $2.82 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on JNJ shares. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. HSBC increased their price objective on shares of Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $189.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.